Director dealings: Indivior director ups stake
(Sharecast News) - Indivior revealed on Wednesday that non-executive director Mark Stejbach had acquired 36,000 ordinary shares in the FTSE 250-listed pharmaceuticals business.
Read moreWed, 15th May 2019 15:41
(Sharecast News) - Indivior revealed on Wednesday that non-executive director Mark Stejbach had acquired 36,000 ordinary shares in the FTSE 250-listed pharmaceuticals business.
Read moreDIRECTOR DEALINGS: 3i team buy; Scopia trims Indivior stake further
Read moreDIRECTOR DEALINGS: IntegraFin COO sells; Chaarat Gold chair buys
Read moreDIRECTOR DEALINGS: Scopia slims 16% Indivior stake as chair buys
Read moreDIRECTOR DEALINGS: Robert Walters CEO sells GBP2.8 million in shares
Read moreIN BRIEF: Indivior to commence USD100 million share repurchase program
Read moreIN BRIEF: Indivior unveils profit hike and USD100 million buyback
Read moreLONDON MARKET MIDDAY: Investors cheer dividend hikes and buyback plans
Read more(Sharecast News) - Speciality pharmaceuticals company Indivior reiterated its upgraded guidance for 2021 on Thursday, and announced the start of a $100m (£71.71m) share buyback programme, as its first-half net revenue rose to $381m from $303m year-on-year.
Read moreUK earnings, trading statements calendar - next 7 days
Read moreIndivior agrees new loan facilities of USD250 million maturing in 2026
Read more(Sharecast News) - Pharmaceutical firm Indivior said on Thursday that it had entered into an amendment to reprice and extend the maturity of $250.0m worth of term loan facilities.
Read moreLONDON MARKET CLOSE: Lower finish fails to dent FTSE's strong quarter
Read more(Sharecast News) - Workspace: RBC Capital Markets upgrades to outperform with a target price of 1,050p.
Read moreLONDON MARKET MIDDAY: Stocks slide ahead of US ADP jobs report
Read more